London
· Delayed Price · Currency is GBP · Price in USD Esperion Therapeutics Statistics
Total Valuation
LON:0IIM has a market cap or net worth of GBP 163.64 million. The enterprise value is 517.01 million.
| Market Cap | 163.64M |
| Enterprise Value | 517.01M |
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 198.20M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +54.12% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 196.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.81 |
| PB Ratio | -0.50 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.36 |
| EV / Sales | 2.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.66 |
Financial Position
The company has a current ratio of 1.18
| Current Ratio | 1.18 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.92 |
| Interest Coverage | -0.62 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -7.17% |
| Return on Invested Capital (ROIC) | -11.83% |
| Return on Capital Employed (ROCE) | -75.31% |
| Revenue Per Employee | 660,881 |
| Profits Per Employee | -390,106 |
| Employee Count | 304 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.57 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.47% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -52.47% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 60.57 |
| Average Volume (20 Days) | 31,312 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.07 |
Income Statement
In the last 12 months, LON:0IIM had revenue of GBP 200.91 million and -118.59 million in losses. Loss per share was -0.63.
| Revenue | 200.91M |
| Gross Profit | 96.07M |
| Operating Income | -30.93M |
| Pretax Income | -118.59M |
| Net Income | -118.59M |
| EBITDA | -30.89M |
| EBIT | -30.93M |
| Loss Per Share | -0.63 |
Balance Sheet
The company has 88.72 million in cash and 459.75 million in debt, giving a net cash position of -371.03 million.
| Cash & Cash Equivalents | 88.72M |
| Total Debt | 459.75M |
| Net Cash | -371.03M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -329.88M |
| Book Value Per Share | -1.68 |
| Working Capital | 37.01M |
Cash Flow
In the last 12 months, operating cash flow was -77.48 million and capital expenditures -188,854, giving a free cash flow of -77.67 million.
| Operating Cash Flow | -77.48M |
| Capital Expenditures | -188,854 |
| Free Cash Flow | -77.67M |
| FCF Per Share | n/a |
Margins
Gross margin is 47.82%, with operating and profit margins of -15.40% and -59.03%.
| Gross Margin | 47.82% |
| Operating Margin | -15.40% |
| Pretax Margin | -59.03% |
| Profit Margin | -59.03% |
| EBITDA Margin | -15.38% |
| EBIT Margin | -15.40% |
| FCF Margin | n/a |
Dividends & Yields
LON:0IIM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.12% |
| Shareholder Yield | n/a |
| Earnings Yield | -72.47% |
| FCF Yield | -47.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0IIM has an Altman Z-Score of -6.19. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.19 |
| Piotroski F-Score | n/a |